Raymond James Financial Services Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Raymond James Financial Services Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-187	Closed	-$5K	–	2921
2020 Q1	$5K	Hold	187	–	–	﹤0.01%	2408
2019 Q4	$9K	Sell	187 -79	-30%	-$3.83K	﹤0.01%	2831
2019 Q3	$13K	Hold	266	–	–	﹤0.01%	2768
2019 Q2	$24K	Sell	266 -24	-8%	-$2.92K	﹤0.01%	2781
2019 Q1	$43K	Buy	290 +85	+41%	+$16.4K	﹤0.01%	2714
2018 Q4	$32K	Sell	205 -83	-29%	-$15.9K	﹤0.01%	2493
2018 Q3	$70K	Buy	+288	New	+$68.2K	﹤0.01%	2694

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LFAS

Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return

Raymond James Financial Services Advisors's DMK Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2020, closing a stake of 187 shares — an estimated $5K sold.

Raymond James Financial Services Advisors first reported a position in DMK in Q3 2018 and held it in 7 quarters. The position peaked at $70K in Q3 2018. 47 funds tracked by Wall St. Rank hold DMK as of Q2 2020.

Raymond James Financial Services Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2020 after selling out during the quarter.
Raymond James Financial Services Advisors sold 187 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2020, an estimated $5K.
Raymond James Financial Services Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2018 and held it in 7 quarters.
Raymond James Financial Services Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $70K in Q3 2018.
47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.